Bio-Rad Laboratories and 10x Genomics have reached a final settlement to resolve multiple long-running lawsuits in Massachusetts, Delaware, California, Germany, and before the International Trade Commission, according to a news release from Bio-Rad.
The settlement includes a global patent cross-license for patents held by both Bio-Rad and 10x Genomics, resolving outstanding issues in the field of single-cell genomics.
Under the terms of the settlement, Bio-Rad and 10x Genomics have granted each other a non-exclusive, worldwide, royalty-bearing license to develop products and services related to single-cell analysis. Both companies have agreed that each company’s patents are owned and valid.
